+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atherosclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • ID: 4911480
  • Report
  • October 2019
  • Region: Global
  • 177 pages
  • Transparency Market Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Novartis AG
  • MORE
Atherosclerosis Drugs Market - Scope of the Report

the report on the global atherosclerosis drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global atherosclerosis drugs market for the period of 2017-2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global atherosclerosis drugs market for the forecast period.

This report has been prepared after extensive primary and secondary research. Primary research involves bulk of the research efforts, wherein, analysts carry out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global atherosclerosis drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of the top-down and bottom-up approaches to study various phenomenon in the global atherosclerosis drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global atherosclerosis drugs market. These indices serve as valuable tools for existing market players, as well as for entities interested in entering the global atherosclerosis drugs market.

The report delves into the competition landscape of the global atherosclerosis drugs market. Key players operating in the global atherosclerosis drugs market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global atherosclerosis drugs market that have been profiled in this report.

Key Questions Answered in the Atherosclerosis Drugs Market Report
  • What is the scope of growth of product companies in the atherosclerosis treatment sector?
  • What will be the Y-o-Y growth of the atherosclerosis drugs market between 2019 and 2027?
  • What is the influence of the changing trends in technologies on the global atherosclerosis drugs market?
  • Will North America continue to remain the most profitable regional market for atherosclerosis drug providers?
  • Which factors will impede the growth of the global atherosclerosis drugs market during the forecast period?
  • Which are the leading companies in the global atherosclerosis drugs market?
Research Methodology

A unique research methodology has been utilized to conduct comprehensive research on the growth of the global atherosclerosis drugs market, and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global atherosclerosis drugs market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of The study on the atherosclerosis drugs market as primary sources.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from atherosclerosis drugs market leaders. Access to extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global atherosclerosis drugs market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching estimates on the future prospects of the global atherosclerosis drugs market more reliably and accurately.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Amgen Inc.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Hoffmann-La Roche Ltd
  • Mylan N.V.
  • Novartis AG
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atherosclerosis Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases
4.3.1.2. Development of New Treatments
4.3.1.3. Rising Awareness about Cardiovascular Diseases
4.3.2. Restraints
4.3.2.1. Availability of Generic Products
4.3.2.2. Low Diagnostic Rate
4.3.3. Opportunities
4.4. Global Atherosclerosis Drugs Market Analysis and Forecast, 2017–2027

5. Market Outlook
5.1. Clinical Trial Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Brand Analysis

6. Global Atherosclerosis Drugs Market Analysis and Forecast, By Drug Class
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.2.1. Anti-platelet Medications
6.2.2. Cholesterol Lowering Medications
6.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
6.2.4. Beta Blockers
6.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
6.2.6. Calcium Channel Blockers
6.2.7. Diuretics
6.2.8. Others
6.3. Global Atherosclerosis Drugs Market Attractiveness, by Drug Class

7. Global Atherosclerosis Drugs Market Analysis and Forecast, By Distribution Channel
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.2.1. Retail Pharmacies
7.2.2. Hospital Pharmacies
7.2.3. Online Pharmacies
7.3. Global Atherosclerosis Drugs Market Attractiveness, by Distribution Channel

8. Global Atherosclerosis Drugs Market Analysis and Forecast, By Region
8.1. Key Findings
8.2. Global Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Atherosclerosis Drugs Market Attractiveness, by region

9. North America Atherosclerosis Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. Anti-platelet Medications
9.2.2. Cholesterol Lowering Medications
9.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
9.2.4. Beta Blockers
9.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
9.2.6. Calcium Channel Blockers
9.2.7. Diuretics
9.2.8. Others
9.3. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Online Pharmacies
9.4. North America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Atherosclerosis Drugs Market Attractiveness
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Atherosclerosis Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. Anti-platelet Medications
10.2.2. Cholesterol Lowering Medications
10.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
10.2.4. Beta Blockers
10.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
10.2.6. Calcium Channel Blockers
10.2.7. Diuretics
10.2.8. Others
10.3. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country Sub/region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Atherosclerosis Drugs Market Attractiveness
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Atherosclerosis Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. Anti-platelet Medications
11.2.2. Cholesterol lowering medications
11.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
11.2.4. Beta blockers
11.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
11.2.6. Calcium Channel Blockers
11.2.7. Diuretics
11.2.8. Others
11.3. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Atherosclerosis Drugs Market Attractiveness
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Atherosclerosis Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. Anti-platelet Medications
12.2.2. Cholesterol Lowering Medications
12.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
12.2.4. Beta blockers
12.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
12.2.6. Calcium Channel Blockers
12.2.7. Diuretics
12.2.8. Others
12.3. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Atherosclerosis Drugs Market Attractiveness
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Atherosclerosis Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. Anti-platelet medications
13.2.2. Cholesterol Lowering Medications
13.2.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
13.2.4. Beta blockers
13.2.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
13.2.6. Calcium Channel Blockers
13.2.7. Diuretics
13.2.8. Others
13.3. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Atherosclerosis Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Atherosclerosis Drugs Market Attractiveness
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Key Company’s Market Ranking Analysis
14.3. Company Profiles
14.3.1. GlaxoSmithKline Plc
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Sanofi
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Hoffmann-La Roche Ltd
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Bayer AG
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Mylan N.V.
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Amgen Inc.
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. Pfizer, Inc.
14.3.10.1. Company Overview
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GlaxoSmithKline Plc
  • Sanofi
  • Hoffmann-La Roche Ltd
  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Mylan N.V.
  • Amgen Inc.
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll